PET Scan of Brain Metabolism in Relation to Age and Disease
Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease
Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease
Sponsor study identifier
Secondary identifiers
observational
123
1 country
1
Study Start
September 1994
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
August 2002
Date type not reportedThis date has not been verified as actual or estimated.
The main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients. As areas of the brain become more active blood flow into and out of these areas increase. In addition to oxygen and glucose, the brain uses chemical compounds known as phospholipids. These phospholipids make up the covering of nerve cells that assist in the transfer of information from cell to cell. Without phospholipids brain cell activity may become abnormal and cause problems in the nervous system. Certain diseases like Alzheimer's disease and brain tumors can affect blood flow to the brain and change the way the brain metabolizes phospholipids. In addition to diseases, changes in the brain occur with normal healthy aging. This study is designed to use PET scan to measure changes in blood flow and changes in phospholipid metabolism. Using this technique, researchers can improve their understanding of how certain diseases change the shape and function of the brain.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2002
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 1994
Date type not reportedThis date has not been verified as actual or estimated.
January 18, 2000
Actual (reported)January 19, 2000
Actual (reported)August 2002
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892, United States
Baudier J, Cole RD. Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids. J Biol Chem. 1987 Dec 25;262(36):17577-83.
Belfrage P, Vaughan M. Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides. J Lipid Res. 1969 May;10(3):341-4.
Brooks DJ, Lammertsma AA, Beaney RP, Leenders KL, Buckingham PD, Marshall J, Jones T. Measurement of regional cerebral pH in human subjects using continuous inhalation of 11CO2 and positron emission tomography. J Cereb Blood Flow Metab. 1984 Sep;4(3):458-65. doi: 10.1038/jcbfm.1984.65.
First Submitted
January 18, 2000
First Posted
January 19, 2000
Study Start
September 1994
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
August 2002
Date type not reportedThis date has not been verified as actual or estimated.
Nefiracetam in the Treatment of Alzheimer's Disease
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Last Updated
March 4, 2008
Record last verified: 2002-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: